Los Angeles Capital Management LLC Invests $379,000 in Immunome, Inc. (NASDAQ:IMNM)

Los Angeles Capital Management LLC acquired a new stake in Immunome, Inc. (NASDAQ:IMNM) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 35,721 shares of the company’s stock, valued at approximately $379,000. Los Angeles Capital Management LLC owned about 0.06% of Immunome as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its holdings in Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after buying an additional 302,916 shares during the period. Victory Capital Management Inc. raised its position in shares of Immunome by 48.1% in the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after acquiring an additional 237,497 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Immunome by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after purchasing an additional 144,557 shares during the period. Magnus Financial Group LLC boosted its position in shares of Immunome by 107.8% during the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock valued at $569,000 after purchasing an additional 27,777 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after purchasing an additional 85,580 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Monday, January 13th. Stephens began coverage on shares of Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 target price on the stock. Finally, Piper Sandler cut their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $28.60.

Insider Buying and Selling

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 8.60% of the stock is owned by company insiders.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $8.94 on Tuesday. The firm has a market cap of $713.21 million, a P/E ratio of -1.10 and a beta of 1.90. Immunome, Inc. has a 52-week low of $8.55 and a 52-week high of $30.96. The business’s 50 day simple moving average is $10.29 and its two-hundred day simple moving average is $12.13.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.